8-K: BioNTech and Autolus Forge Strategic CAR-T Cell Therapy Collaboration, BioNTech Invests $200 Million

BioNTech and Autolus have entered a strategic collaboration to advance their CAR-T cell therapy programs, with BioNTech investing $200 million in Autolus.

Summary

• Autolus Therapeutics and BioNTech SE have announced a strategic collaboration to advance their respective CAR-T cell therapy programs.
• BioNTech will invest $200 million in Autolus through a private placement of American Depositary Shares.
• BioNTech will make an upfront payment of $50 million to Autolus, which includes $10 million for a license and option agreement and $40 million for rights to future revenues from obe-cel sales.
• Autolus is eligible for up to $582 million in total payments, including upfront payments, milestone payments, option exercise fees, and additional payments related to obe-cel revenue interest.
• BioNTech gains an exclusive license to certain Autolus binders and the right to exploit products expressing these binders in vivo.
• BioNTech has options to acquire additional rights to Autolus clinical-stage product candidates, binders, and technologies.
• Autolus will retain full rights to and control of the development and commercialization of its lead product candidate, obecabtagene autoleucel (obe-cel).
• BioNTech will support the expansion of the clinical development program for obe-cel and will receive a low single-digit royalty on net sales, which may increase to a mid-single digit percentage upon achievement of certain regulatory milestones.
• BioNTech has the option to access Autolus' manufacturing and commercial infrastructure to accelerate the development of its BNT211 program.
• Autolus will lead the development and commercialization of AUTO1/22 and AUTO6NG, with BioNTech having an option to co-fund development and co-commercialize these candidates.

Sentiment

Score: 9

Explanation: The document conveys a highly positive sentiment due to the significant investment, strategic collaboration, and potential for future growth and revenue. The deal is a major win for Autolus and also positions BioNTech well in the CAR-T space.

Positives

• The collaboration provides Autolus with significant funding through BioNTech's $200 million investment and $50 million upfront payment.
• Autolus retains full rights to and control of the development and commercialization of its lead product candidate, obe-cel.
• The partnership allows Autolus to leverage BioNTech's resources and expertise to expand the clinical development of obe-cel.
• Autolus gains access to BioNTech's manufacturing and commercial capabilities, potentially accelerating the development of its own programs.
• The deal provides Autolus with potential revenue streams through milestone payments, royalties, and profit-sharing arrangements.
• The collaboration validates Autolus' technology and its potential in the CAR-T cell therapy space.

Negatives

• Autolus will pay BioNTech a low single-digit percentage of annual net sales of obe-cel products, which may increase to a mid-single digit percentage in exchange for milestone payments.
• BioNTech has the right to terminate the License Agreement, in whole or in part, for any or no reason upon a specified period of prior written notice to the Company.
• The deal includes options for BioNTech to acquire additional rights to Autolus' technologies, which could potentially limit Autolus' future flexibility.

Risks

• The success of the collaboration depends on the ability of both companies to execute their respective development plans.
• There is a risk that clinical trials for obe-cel, BNT211, AUTO1/22, and AUTO6NG may not be successful.
• Regulatory approvals for these therapies are not guaranteed.
• The commercial success of these therapies will depend on market acceptance and competition.
• There is a risk that BioNTech may not exercise all of its options, limiting the potential financial benefits for Autolus.
• The collaboration could be terminated by BioNTech, which would impact Autolus' plans.

Future Outlook

The collaboration aims to accelerate the development and commercialization of both companies' CAR-T cell therapy programs. BioNTech plans to initiate its first pivotal Phase 2 trial evaluating BNT211 in 2L+ germ cell tumors in 2024. Autolus will continue to develop and commercialize obe-cel, AUTO1/22, and AUTO6NG. The companies will explore further opportunities to leverage Autolus' technology beyond autologous cell therapies.

Management Comments

• Prof. Ugur Sahin, M.D., CEO and Co-Founder of BioNTech, stated that the collaboration enables the expansion of the BNT211 program and provides access to Autolus' manufacturing facilities and cell targeting tools.
• Dr. Christian Itin, Chief Executive Officer of Autolus, highlighted the opportunity to leverage core capabilities, accelerate pipeline programs, and expand opportunities beyond autologous cell therapies.

Industry Context

This collaboration reflects a growing trend in the biopharmaceutical industry towards strategic partnerships to accelerate the development and commercialization of innovative therapies, particularly in the field of cell and gene therapy. The deal also highlights the increasing interest in CAR-T cell therapies for cancer treatment and the importance of manufacturing capabilities in this space.

Comparison to Industry Standards

• The upfront investment of $200 million by BioNTech is a significant commitment, comparable to other major collaborations in the cell therapy space.
• The potential for Autolus to receive up to $582 million in total payments is also substantial, reflecting the value of its technology and pipeline.
• The structure of the deal, with BioNTech gaining access to Autolus' manufacturing and commercial infrastructure, is similar to other collaborations where larger companies leverage the capabilities of smaller biotech firms.
• The royalty rates and milestone payments are within the typical range for licensing agreements in the biopharmaceutical industry.
• The focus on both autologous and in vivo cell therapies aligns with the broader industry trend of exploring multiple approaches to cell-based cancer treatments.
• The collaboration between BioNTech and Autolus is similar to other partnerships between large pharmaceutical companies and smaller biotech firms, such as the collaboration between Gilead and Kite Pharma in the CAR-T space.

Management Changes

Stakeholder Impact

• Shareholders of Autolus will benefit from the significant investment and potential for future growth.
• Employees of Autolus may see increased job security and opportunities for advancement.
• Patients may benefit from the accelerated development of new cancer therapies.
• BioNTech will gain access to valuable technology and manufacturing capabilities.
• Suppliers and partners of both companies may see increased business opportunities.

Next Steps

• BioNTech will proceed with the private placement of ADSs in Autolus.
• The companies will work to finalize the license and option agreement.
• BioNTech will explore the use of Autolus' manufacturing and commercial infrastructure.
• Autolus will continue the development of obe-cel, AUTO1/22, and AUTO6NG.
• BioNTech will initiate its first pivotal Phase 2 trial evaluating BNT211 in 2L+ germ cell tumors in 2024.
• The companies will explore further opportunities to leverage Autolus' technology beyond autologous cell therapies.

Key Dates

Keywords

CAR-T cell therapy, BioNTech, Autolus Therapeutics, obe-cel, BNT211, AUTO1/22, AUTO6NG, immunotherapy, oncology, license agreement, private placement, milestone payments, royalties, manufacturing, commercialization